ATRA — Atara Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $86.22m
- $117.89m
- $120.77m
Atara Biotherapeutics sinks as FDA rejects cancer drug application
Brief: Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA
US FDA declines to approve Atara's therapy for rare blood cancer
Brief: Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)
Brief: Atara Biotherapeutics Inc - Entered Fourth Amendment With Pierre Fabre - SEC Filing
Atara Biotherapeutics Q3 revenue beats estimates
U.S. STOCKS ON THE MOVE- Applovin, Ford Motor, Alto Neuroscience
Atara rises on plan to lay off staff
Brief: Atara Biotherapeutics Inc - Gregory A. Ciongoli Appointed As Chair Of Atara Board - SEC Filing
Brief: Atara Biotherapeutics Announces Changes To Its Board Of Directors
Atara Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Atara Biotherapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview
Brief: Atara Biotherapeutics Provides Regulatory And Business Updates On Tabelecleucel (Tab-Cel)
U.S. STOCKS ON THE MOVE-Xponential Fitness, Phillips 66, Amazon.com
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Boeing, Abbott
Atara Biotherapeutics rises after direct stock offering, business update
Atara Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Atara Biotherapeutics To Reduce Workforce By 30%
Brief: Atara Biotherapeutics Says FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials